Related Experiment Videos
Clinical trial of cefuroxime axetil in children
Insights
Cefuroxime axetil tablets showed variable effectiveness in treating pediatric lower respiratory tract infections, with some cases unresolved. Further research is needed to optimize cefuroxime axetil
Area of Science:
- Pediatric infectious diseases
- Pharmacokinetics and drug efficacy
- Respiratory medicine
Background:
- Lower respiratory tract infections (LRTI) are common in children.
- Cefuroxime axetil is a commonly prescribed antibiotic for bacterial infections.
Purpose of the Study:
- To evaluate the efficacy and tolerability of cefuroxime axetil tablets in pediatric patients with LRTI.
- To assess cefuroxime axetil absorption and serum levels in children.
Main Methods:
- A cohort of 12 children with 14 LRTI episodes received cefuroxime axetil (15-32 mg/kg/day).
- Clinical outcomes (cure, improvement, failure) were assessed.
- Serum drug levels and presence of Haemophilus influenzae post-treatment were monitored.
Main Results:
- Six infections were cured, and seven improved; one case was not detailed.
- Haemophilus influenzae persisted in four post-treatment cases.
- Significant variability in serum cefuroxime levels was observed, suggesting potential absorption or penetration issues.
Conclusions:
- Cefuroxime axetil demonstrated moderate efficacy in pediatric LRTI but showed variable absorption and penetration.
- The drug was generally well-tolerated by pediatric patients.
- Further investigation into optimizing cefuroxime axetil delivery or exploring alternative treatments for resistant organisms is warranted.
Abstract:
Cefuroxime axetil tablets were given to 12 children (aged 19 months to 13.5 years) for a total of 14 episodes of lower respiratory tract infection. Doses ranged from 15 to 32 mg/kg/day. Six infections were regarded as cured and seven improved. In four cases, Haemophilus influenzae was present at the end of treatment. Serum levels of cefuroxime showed great variability. Absorption and penetration of the drug into the lower respiratory mucosa may not be sufficient to kill organisms which are sensitive in vitro. Cefuroxime axetil tablets were acceptable to most children.